First Case Report of Primary Carnitine Deficiency Manifested as Intellectual Disability and Autism Spectrum Disorder
- PMID: 31200524
- PMCID: PMC6628273
- DOI: 10.3390/brainsci9060137
First Case Report of Primary Carnitine Deficiency Manifested as Intellectual Disability and Autism Spectrum Disorder
Abstract
Systemic primary carnitine deficiency (PCD) is a genetic disorder caused by decreased or absent organic cation transporter type 2 (OCTN2) carnitine transporter activity, resulting in low serum carnitine levels and decreased carnitine accumulation inside cells. In early life, PCD is usually diagnosed as a metabolic decompensation, presenting as hypoketotic hypoglycemia, Reye syndrome, or sudden infant death; in childhood, PCD presents with skeletal or cardiac myopathy. However, the clinical presentation of PCD characterized by autism spectrum disorder (ASD) with intellectual disability (ID) has seldom been reported in the literature. In this report, we describe the clinical features of a seven-year-old girl diagnosed with PCD who presented atypical features of the disease, including a developmental delay involving language skills, concentration, and attention span, as well as autistic features and brain alterations apparent in magnetic resonance imaging. We aim to highlight the difficulties related to the diagnostic and therapeutic approaches used to diagnose such patients. The case reported here presented typical signs of PCD, including frequent episodes of hypoglycemia, generalized muscle weakness, decreased muscle mass, and physical growth deficits. A molecular genetic study confirmed the definitive diagnosis of the disease (c.1345T>G (p.Y449D)) in gene SLC22A5, located in exon 8. PCD can be accompanied by less common clinical signs, which may delay its diagnosis because the resulting global clinical picture can closely resemble other metabolic disorders. In this case, the patient was prescribed a carnitine-enriched diet, as well as oral carnitine at a dose of 100 mg/kg/day. PCD has a better prognosis if it is diagnosed and treated early; however, a high level of clinical suspicion is required for its timely and accurate diagnosis.
Keywords: autism; carnitine; intellectual disability; muscle; rare disease.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Figures


Similar articles
-
A Rare Treatable Cause of Cardiomyopathy: Primary Carnitine Deficiency.Mol Syndromol. 2024 Mar;15(2):156-160. doi: 10.1159/000534932. Epub 2023 Nov 27. Mol Syndromol. 2024. PMID: 38585546 Free PMC article.
-
Biochemical, Molecular, and Clinical Characterization of Patients With Primary Carnitine Deficiency via Large-Scale Newborn Screening in Xuzhou Area.Front Pediatr. 2019 Feb 26;7:50. doi: 10.3389/fped.2019.00050. eCollection 2019. Front Pediatr. 2019. PMID: 30863740 Free PMC article.
-
Clinical, biochemical, and molecular genetic characteristics of patients with primary carnitine deficiency identified by newborn screening in Shanghai, China.Front Genet. 2022 Dec 8;13:1062715. doi: 10.3389/fgene.2022.1062715. eCollection 2022. Front Genet. 2022. PMID: 36568374 Free PMC article.
-
Carnitine transport and fatty acid oxidation.Biochim Biophys Acta. 2016 Oct;1863(10):2422-35. doi: 10.1016/j.bbamcr.2016.01.023. Epub 2016 Jan 29. Biochim Biophys Acta. 2016. PMID: 26828774 Free PMC article. Review.
-
Clinical characteristics of primary carnitine deficiency: A structured review using a case-by-case approach.J Inherit Metab Dis. 2022 May;45(3):386-405. doi: 10.1002/jimd.12475. Epub 2022 Feb 3. J Inherit Metab Dis. 2022. PMID: 34997761 Free PMC article. Review.
Cited by
-
Ratings of the Effectiveness of Nutraceuticals for Autism Spectrum Disorders: Results of a National Survey.J Pers Med. 2021 Aug 31;11(9):878. doi: 10.3390/jpm11090878. J Pers Med. 2021. PMID: 34575655 Free PMC article.
-
Emerging biomarkers in autism spectrum disorder: a systematic review.Ann Transl Med. 2019 Dec;7(23):792. doi: 10.21037/atm.2019.11.53. Ann Transl Med. 2019. PMID: 32042808 Free PMC article. Review.
-
Effects of l-Carnitine in Patients with Autism Spectrum Disorders: Review of Clinical Studies.Molecules. 2019 Nov 22;24(23):4262. doi: 10.3390/molecules24234262. Molecules. 2019. PMID: 31766743 Free PMC article. Review.
-
A Review on the Role of Genetic Mutations in the Autism Spectrum Disorder.Mol Neurobiol. 2023 Sep;60(9):5256-5272. doi: 10.1007/s12035-023-03405-9. Epub 2023 Jun 6. Mol Neurobiol. 2023. PMID: 37278883 Review.
-
A report of a pedigree with compound heterozygous mutations in the SLC22A5 gene.Front Pediatr. 2023 Jun 6;11:985720. doi: 10.3389/fped.2023.985720. eCollection 2023. Front Pediatr. 2023. PMID: 37351314 Free PMC article.
References
-
- Iacobazzi V., Invernizzi F., Baratta S., Pons R., Chung W., Garavaglia B., Dionisi-Vici C., Ribes A., Parini R., Huertas M.D., et al. Molecular and functional analysis ofSLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency. Hum. Mutat. 2004;24:312–320. doi: 10.1002/humu.20085. - DOI - PubMed
-
- Radke J., Stenzel W., Goebel H.H. Neurometabolic and neurodegenerative diseases in children. Handb. Clin. Neurol. 2017;145:133–146. - PubMed
Publication types
LinkOut - more resources
Full Text Sources